Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer

Jereczek‐Fossa, Barbara Alicja; Beltramo, G.; Fariselli, Laura; Fodor, C.; Santoro, Luigi; Vavassori, Andrea; Zerini, Dario; Gherardi, F.; Ascione, Carmen; Bossi-Zanetti, Isa; Mauro, Roberta Di; Bregantin, Achille; Bianchi, Livia; Cobelli, Ottavio De; Orecchia, Roberto

doi:10.1016/j.ijrobp.2010.11.031

Cited by 219 publications

(248 citation statements)

References 23 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…Помимо хирургического лечения у больных с прогрессированием РПЖ и единичными метастазами в ЛУ в настоящее время широко изучает-ся другой терапевтический подход. Как известно, ЛТ активно используют в лечении пациентов с РПЖ [32][33][34][35][36][37][38][39][40][41]. В последнее время все чаще применяют стерео-таксическую ЛТ.…”

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

“…В последнее время все чаще применяют стерео-таксическую ЛТ. Полученные результаты позволяют принципиально изменить подход к лечению больных с прогрессированием РПЖ [33]. Преимуществом дан-ного вида терапии является возможность лечения больных с тяжелой сопутствующей патологией, кото-рым противопоказано хирургическое вмешательство.…”

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

See 1 more Smart Citation

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев¹,

Нюшко²,

Krasheninnikov³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

Section: диагностика и лечение опухолей мочеполовой системы рак предunclassified

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев¹,

Нюшко²,

Krasheninnikov³

et al. 2016

Cancer Urology

View full text Add to dashboard Cite

“…The biochemical response was classified as complete response (reduction of .50% of the initial PSA0 value), partial response (reduction of between 10% and 50% of the initial PSA0 value), stable disease (within 10% of initial values), or progression of disease (increase in serum PSA value of .10%) (15,21).…”

Section: Treatment and Follow-upmentioning

confidence: 99%

Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹C-Choline PET/CT Predictive of Survival Outcomes?

et al. 2015

View full text Add to dashboard Cite

PET/CT is a valuable tool to detect lymph node (LN) metastases in patients with biochemical failure after primary treatment for prostate cancer (PCa). The aim was to assess the predictive role of imaging parameters derived by 11 C-choline PET/CT on survival outcomesoverall survival, locoregional relapse-free survival, clinical relapsefree survival (cRFS), and biochemical relapse-free survival (bRFS)-in patients treated with helical tomotherapy (HTT) for LN recurrence. Methods: This retrospective study included 68 patients affected by PCa (mean age, 68 y; age range, 51-81 y) with biochemical recurrence after primary treatment (median prostate-specific antigen values obtained at the time of PET/CT scan, 2.42 ng/mL; range, 0.61-27.56 ng/mL) who underwent 11 C-choline PET/CT from January 2005 to January 2013 and were treated with HTT in correspondence of the pathologic choline LN uptake. PET-derived parameters, including maximum/mean standardized uptake value (SUV max and SUV mean , respectively) and metabolic tumor volume (MTV) with a threshold of 40%, 50%, and 60% were calculated. The best cutoff values of PET-derived parameters discriminating between patients with and without relapse, after treatment guided by PET, were assessed by receiver-operating-characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analysis including the most predictive PET-derived parameters and survival outcomes were performed. Results: The median follow-up was 20 mo (mean, 26 mo; range, 3-97 mo). 11 C-choline PET/CT showed pathologic LN uptake in 4 patients at the pelvic level, in 5 at the abdominal level, in 13 at both the pelvic and the abdominal level, and in 46 at the abdominal or pelvic or other sites. The 2-y overall survival, locoregional relapse-free survival, cRFS, and bRFS were 87%, 91%, 51%, and 40%, respectively. On the basis of ROC curves, the most discriminative cutoff value for MTV values was an MTV threshold of 60% (MTV60) of greater than 0.64 cm 3 . No significant cutoff values were found for SUV max or SUV mean at univariate analysis, whereas MTV60 was confirmed as an independent predictor in multivariate analysis and significantly correlated with bRFS and cRFS. MTV60 and extrapelvic disease well predict the risk of cRFS. Conclusion: 11 C-choline PET/CT performed as a guide for HTT on LN recurrence is predictive of survival. In particular, MTV60 and extrapelvic disease were the best predictors of tumor response for bRFS and cRFS in PCa patients with LN recurrence after primary treatment. This information may be useful in emerging treatment strategies.

show abstract

“…Surgical and/or radiotherapeutical eradication of oligometastases might delay ADT and cancer progression. 61 Recently, the first studies addressing salvage stereotactic body radiotherapy (SBRT) for low-volume metastatic disease were published [61][62][63][64] , showing that clinical progression can be, at least temporarily, slowed down. SBRT is a non-invasive modality allowing the delivery of ablative doses to the tumor while sparing the surrounding normal tissue.…”

Section: Radiotherapeutic Treatment Of Oligometastatic Pcmentioning

confidence: 99%

“…61,62 However, SBRT doses are not standardized and several fractionation schedules co-exist. 62,63 Further prospective trials are necessary investigating the potential of this approach.…”

Section: Radiotherapeutic Treatment Of Oligometastatic Pcmentioning

confidence: 99%

Developments in External Beam Radiotherapy for Prostate Cancer

Lumen

Ost

Praet

et al. 2013

Urology

View full text Add to dashboard Cite

Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer

Cited by 219 publications

References 23 publications

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹C-Choline PET/CT Predictive of Survival Outcomes?

Developments in External Beam Radiotherapy for Prostate Cancer

Contact Info

Product

Resources

About

Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer

Cited by 219 publications

References 23 publications

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?

Developments in External Beam Radiotherapy for Prostate Cancer

Contact Info

Product

Resources

About

Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹C-Choline PET/CT Predictive of Survival Outcomes?